Haleon repurchases shares and cancels 23,788; voting shares revised

Rhea-AI Filing Summary

Haleon plc announced on 15 September 2025 that it purchased 997,991 ordinary shares of
each under the second tranche of its share buyback programme announced 31 July 2025. Of the purchased shares, 23,788 will be cancelled and 974,203 will be held as treasury shares. After settlement the company's registered share capital is 8,952,353,648 ordinary shares of
each, with 2,501,961 held as treasury shares and 8,949,851,687 shares with voting rights.

The announcement notes a full trade breakdown is available via the provided RNS link and on the company's investor website.

Positive

• Execution of buyback: Company purchased 997,991 ordinary shares under the announced programme
• Partial cancellation: 23,788 of the purchased shares will be cancelled, reducing issued share capital
• Updated share counts: Company provided precise post-settlement figures including 8,949,851,687 voting shares for regulatory notification purposes
• Regulatory disclosure: Full individual trade breakdown published via RNS and posted on the company website

Negative

• None.

Insights

Financial Analyst

TL;DR: Haleon executed a near-1.0m share buyback tranche, cancelling a small portion and adding treasury stock, modestly reducing shares outstanding.

The transaction reduces shares in circulation by a combination of cancellation and treasury holdings, updating the voting share count to 8,949,851,687. The buyback size reported here (997,991 shares) is explicitly disclosed but no aggregate tranche value or percentage of total share capital is provided, limiting assessment of magnitude relative to market cap. A full breakdown of individual trades is available via the RNS link for verification of execution prices and timing.

Corporate Governance Expert

TL;DR: The company followed disclosure requirements, provided trade detail links, and updated share capital and voting figures for shareholder notification rules.

Haleon cites the Market Abuse Regulation for trade disclosure and supplies the RNS link and investor-site posting, meeting regulatory transparency expectations. The announcement specifies the exact number of shares cancelled versus held in treasury, and provides the adjusted voting share count that shareholders should use for FCA notification thresholds. There is no discussion of board authorization details or remaining buyback capacity in this notice.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 Form 20-F ☒ Form 40-F ☐               

EXHIBIT INDEX

Exhibit Number	Description
99.1	15 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

15 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 997,991 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	12 September 2025	12 September 2025	12 September 2025
Number of Shares purchased:	997,991	-	-
Highest price paid per Share (p):	366.0000	-	-
Lowest price paid per Share (p):	362.1000	-	-
Volume weighted average price paid per Share (p):	364.3179	-	-

23,788 of the purchased shares will be cancelled and the Company intends to hold 974,203 of the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 2,501,961 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,949,851,687 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/2274Z_1-2025-9-12.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 15, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did Haleon (HLNCF) purchase on 12 September 2025?

Haleon purchased 997,991 ordinary shares under the second tranche of its buyback programme.

How many of the repurchased Haleon shares were cancelled versus held in treasury?

23,788 shares will be cancelled and 974,203 will be held as treasury shares.

What is Haleon's updated number of ordinary shares with voting rights after the buyback?

After settlement the number of ordinary shares with voting rights is 8,949,851,687.

Where can I find the full breakdown of individual trades for Haleon's buyback?

A full breakdown is available at the RNS link provided in the announcement: http://www.rns-pdf.londonstockexchange.com/rns/2274Z_1-2025-9-12.pdf and on www.haleon.com/investors.

Does this announcement include the total monetary value paid for the repurchased shares?

No. The announcement states the number of shares purchased and references individual trade details, but does not disclose an aggregate monetary value in this filing.